Insulet: Medicare can cover insulin device
Zachary Comeau
Insulet is expected to begin operating this space in Acton by the beginning of 2019.
Medical device maker Insulet announced Monday its insulin delivery device, Omnipod, is eligible for Medicare Part D coverage.
The company, headquartered in Billerica and building a 350,000-square-foot manufacturing facility in Acton, said the Centers for Medicare and Medicaid Services has issued guidance clarifying Medicare Part D sponsors can cover such devices.
Insulet, in its press release, said the guidance allows the company to begin working with Medicare Part D carriers. The coverage provides Insulet with a pathway to gain Medicaid coverage at state level.
With Medicare and Medicaid coverage, access to the company’s Omnipod System will expand to about 450,000 Type 1 diabetes patients in the country. Lower-income patients and families will now have access to the system, the company said.
In a statement, Chairman and CEO Patrick Sullivan said Medicare coverage for the device was one of the company’s top priorities.
“We are thrilled more people will be able to choose our innovative and differentiated Omnipod technology, which delivers continuous insulin without the use of tubes and eliminates the stress and anxiety of multiple daily injections,” he said.
WBJ Web Partners
Most Recent
Most Recent
0 Comments